- Cellistic has appointed Jason Conner as Chief Executive Officer, effective immediately.
- Conner will also serve as CEO of Ncardia, the company’s sister business focused on stem cell–based solutions for drug discovery and safety assessment.
Cellistic has appointed Jason Conner as Chief Executive Officer, effective immediately. Conner will also assume the same role at Ncardia, Cellistic’s sister company focused on stem cell–based solutions for drug discovery and safety assessment. He has served on the Board of Directors of the businesses since 2022.
Cellistic provides manufacturing and development services for allogeneic induced pluripotent stem cell (iPSC)-derived cell therapies. The company operates in the cell therapy contract manufacturing sector and works with customers developing immuno-oncology and regenerative medicine therapies.
Conner brings 25 years of experience in the life sciences industry across both services and product organisations. Since 2021, he has worked with Kiniciti, a strategic investment platform that serves as Cellistic’s majority shareholder. Earlier in his career, he held executive roles at Patheon and Thermo Fisher Scientific and began his career in corporate development and strategy at Becton Dickinson.
“Since the Cellistic business was launched in 2023, the team has made incredible progress strengthening our iPSC platform capabilities and driving GMP manufacturing operations, the combination of which offers a unique value proposition for our customers.”
Jason Conner
According to the company’s board, Conner has worked closely with the leadership teams of both Cellistic and Ncardia in recent years. The appointment follows the company’s efforts to expand its iPSC platform capabilities and manufacturing operations supporting the development of cell-based therapies.
